Gibson Christopher
- SEC CIK
- 0001856369
In the past year, 16 open-market sale filings worth $3.37M and no purchases.
Current role at each company
- RXRX Recursion Pharmaceuticals, Inc.Directoras of Jun 5, 2026
- PACB Pacific Biosciences of California, Inc.Directoras of Jun 4, 2026
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- $3.37M
- 16 filings
- Net
- −$3.37M
- Bought minus sold
- Companies
- 1
- With open-market trades
Trades
Every Form 4 that lists Gibson Christopher as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
RXRX Recursion Pharmaceuticals, Inc.
Director104 trades
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Dec 9, 2021 (view filing) | Dec 7 | 2 days | Gibson ChristopherChief Executive Officer | SSaleClass B Common Stock | −16.7K | $20.48 | −$341.3K | −0.2%8.20M after | 2 lots |
| Dec 9, 2021 (view filing) | Dec 7 | 2 days | Gibson ChristopherChief Executive Officer | SSaleClass B Common Stock | −3.13K | $20.51 | −$64.1K | −2.1%146.9K after | 2 lots |
| Dec 10, 2021 (view filing) | Dec 8-9 | 2 days | Gibson ChristopherChief Executive Officer | SSaleClass A Common Stock | −11.8K | $20.14 | −$236.6K | −33.4%23.5K after | 3 lots |
| Dec 15, 2021 (view filing) | Dec 13 | 2 days | Gibson ChristopherChief Executive Officer | SSaleClass A Common Stock | −100 | $20.02 | −$2.00K | −0.4%23.5K after | |
| Dec 20, 2021 (view filing) | Dec 16 | 4 days | Gibson ChristopherChief Executive Officer | SSaleClass A Common Stock | −200 | $20.01 | −$4.00K | −0.8%23.5K after | |
| Jan 14, 2022 (view filing) | Jan 13-14 | 1 day | Gibson ChristopherChief Executive Officer | SSaleClass A Common Stock | −341.0K | $13.76 | −$4.69M | −93.6%23.5K after | 3 lots |
| Feb 2, 2022 (view filing) | Jan 31 | 2 days | Gibson ChristopherChief Executive Officer | SSaleClass A Common Stock | −19.9K | $11.73 | −$232.9K | −45.8%23.5K after | |
| Feb 24, 2022 (view filing) | Feb 22 | 2 days | Gibson ChristopherChief Executive Officer | SSaleClass A Common Stock | −100.0K | $10.22 | −$1.02M | −29.9%234.0K after | |
| Mar 9, 2022 (view filing) | Mar 7 | 2 days | Gibson ChristopherChief Executive Officer | SSaleClass A Common Stock | −300.0K | $7.30 | −$2.19M | −56.2%234.0K after | |
| Mar 15, 2022 (view filing) | Mar 11-15 | 4 days | Gibson ChristopherChief Executive Officer | SSaleClass A Common Stock | −336.1K | $6.48 | −$2.18M | −59.0%234.0K after | 3 lots |